小分子靶向药物和生物制剂治疗斑秃的研究进展

doi:10.35541/cjd.20200563

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (12): 1118-1121.doi: 10.35541/cjd.20200563

小分子靶向药物和生物制剂治疗斑秃的研究进展

丁雨薇乔建军方红

浙江大学医学院附属第一医院皮肤科，杭州 310003

收稿日期:2020-06-08 修回日期:2020-10-26 发布日期:2022-12-05
通讯作者: 方红 E-mail:fanghongzy@zju.edu.cn
基金资助:
国家自然科学基金（81972931）

Small-molecule targeted drugs and biological agents for alopecia areata

Ding Yuwei, Qiao Jianjun, Fang Hong

Department of Dermatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

Received:2020-06-08 Revised:2020-10-26 Published:2022-12-05
Contact: Fang Hong E-mail:fanghongzy@zju.edu.cn
Supported by:
National Natural Science Foundation of China（81972931）

摘要/Abstract

摘要： 【摘要】斑秃的传统治疗方法疗效欠佳，尤其是对中重度斑秃和特殊类型斑秃。小分子靶向药物和生物制剂较传统疗法起效快、疗效显著，但部分患者治疗期间会出现感染等不良反应或停药后会复发，其有效性和安全性仍需进一步评估。本文综述小分子靶向药物和生物制剂在斑秃治疗中的研究进展。

关键词: 斑秃, 分子靶向治疗, 生物疗法

Abstract: 【Abstract】 Traditional therapies for alopecia areata, especially moderate to severe alopecia areata and special types of alopecia areata, remain unsatisfactory. Compared with traditional therapies, small-molecule targeted drugs and biological agents have advantages of more rapid and marked efficacy, however, some patients may experience adverse reactions such as infections during treatment or relapses after drug withdrawal. Thus, their efficacy and safety still need to be further evaluated. This review summarizes research progress in small-molecule targeted drugs and biological agents in the treatment of alopecia areata.

Key words: Alopecia areata, Molecular targeted therapy, Biological therapy

丁雨薇乔建军方红. 小分子靶向药物和生物制剂治疗斑秃的研究进展[J]. 中华皮肤科杂志, 2022,55(12):1118-1121. doi:10.35541/cjd.20200563

Ding Yuwei, Qiao Jianjun, Fang Hong. Small-molecule targeted drugs and biological agents for alopecia areata[J]. Chinese Journal of Dermatology, 2022, 55(12): 1118-1121.doi:10.35541/cjd.20200563

参考文献 41

［1］	中华医学会皮肤性病学分会毛发学组. 中国斑秃诊疗指南（2019）［J］. 临床皮肤科杂志, 2020,49（2）:69⁃72. doi: 10.16761/ j.cnki.1000⁃4963.2020.02.002.
［2］	Shreberk⁃Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review［J］. J Am Acad Dermatol, 2017,76（4）:745⁃753.e19. doi: 10.1016/j.jaad.2016.12. 004.
［3］	Pratt CH, King LE Jr, Messenger AG, et al. Alopecia areata［J］. Nat Rev Dis Primers, 2017,3:17011. doi: 10.1038/nrdp.2017.11.
［4］	Triyangkulsri K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata［J］. Drug Des Devel Ther, 2018,12:2323⁃2335. doi: 10.2147/DDDT.S172638.
［5］	Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis［J］. J Invest Dermatol, 2014,134（12）:2988⁃2990. doi: 10.1038/jid.2014.260.
［6］	Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata［J］. JCI Insight, 2016,1（15）:e89776. doi: 10.1172/jci.insight.89776.
［7］	Guo L, Feng S, Sun B, et al. Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2020,34（1）:192⁃201. doi: 10.1111/jdv.15937.
［8］	Mackay⁃Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate⁃to⁃severe alopecia areata［J］. JCI Insight, 2016,1（15）:e89790. doi: 10.1172/ jci.insight.89790.
［9］	Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib［J］. EBioMedicine, 2015,2（4）:351⁃355. doi: 10.1016/j.ebiom.2015. 02.015.
［10］	Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib［J］. JAAD Case Rep, 2019,5（10）:892⁃894. doi: 10.1016/j.jdcr.2019.07.005.
［11］	Lee JS, Huh CH, Kwon O, et al. Nail involvement in patients with moderate⁃to⁃severe alopecia areata treated with oral tofacitinib［J］. J Dermatolog Treat, 2018,29（8）:819⁃822. doi: 10.1080/09546634.2018.1466024.
［12］	Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children［J］. J Am Acad Dermatol, 2019,80（2）:568⁃570. doi: 10.1016/j.jaad.2018.08.041.
［13］	Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（4）:1164⁃1166. doi: 10.1016/j.jaad.2018.12.041.
［14］	Peterson DM, Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient［J］. JAAD Case Rep, 2020,6（4）:257⁃259. doi: 10.1016/j.jdcr.2020.02.007.
［15］	Jabbari A, Sansaricq F, Cerise J, et al. An open⁃label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch⁃type alopecia areata, totalis, and universalis［J］. J Invest Dermatol, 2018,138（7）:1539⁃1545. doi: 10.1016/j.jid. 2018.01.032.
［16］	Chen YY, Lin SY, Chen YC, et al. Low⁃dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost⁃saving regimen［J］. Eur J Dermatol, 2019,29（6）:667⁃669. doi: 10.1684/ejd.2019.3668.
［17］	Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata［J］. Lancet, 2019,393（10169）:318⁃319. doi: 10.1016/S0140⁃6736（18）32987⁃8.
［18］	Shivanna CB, Shenoy C, Priya RA. Tofacitinib （selective janus kinase inhibitor 1 and 3）: a promising therapy for the treatment of alopecia areata: a case report of six patients［J］. Int J Trichology, 2018,10（3）:103⁃107. doi: 10.4103/ijt.ijt_21_18.
［19］	Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis［J］. JAMA Dermatol, 2016,152（4）:490⁃491. doi: 10.1001/jamadermatol.2015.4445.
［20］	Craiglow BG. Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes［J］. JAAD Case Rep, 2018,4（10）:988⁃989. doi: 10.1016/j.jdcr.2018.07.018.
［21］	Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors ⁃ a double blind, placebo, and active controlled pilot study［J］. Int J Dermatol, 2018,57（12）:1464⁃1470. doi: 10.1111/ijd.14192.
［22］	Deeb M, Beach RA. A case of topical ruxolitinib treatment failure in alopecia areata［J］. J Cutan Med Surg, 2017,21（6）:562⁃563. doi: 10.1177/1203475417716363.
［23］	Keren A, Shemer A, Ullmann Y, et al. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo［J］. J Dermatol Sci, 2015,77（1）:74⁃76. doi: 10.1016/j.jdermsci.2014.11.009.
［24］	Magdaleno⁃Tapial J, Valenzuela⁃Oñate C, Sánchez⁃Carazo JL, et al. Improvement of alopecia areata with apremilast［J］. Australas J Dermatol, 2019,60（2）:144⁃145. doi: 10.1111/ajd.12934
［25］	Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata［J］. J Am Acad Dermatol, 2017,77（4）:773⁃774. doi: 10.1016/j.jaad.2017.05.034.
［26］	Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo⁃controlled single⁃center pilot study of the safety and efficacy of apremilast in subjects with moderate⁃to⁃severe alopecia areata［J］. Arch Dermatol Res, 2019,311（1）:29⁃36. doi: 10.1007/s00403⁃018⁃1876⁃y.
［27］	Weber B, Radakovic S, Tanew A. Apremilast for extensive and treatment⁃resistant alopecia areata: a retrospective analysis of five patients［J］. Eur J Dermatol, 2020,30（2）:165⁃168. doi: 10.1684/ejd.2020. 3749.
［28］	Wang TT, Yang J, Zhang Y, et al. IL⁃2 and IL⁃15 blockade by BNZ⁃1, an inhibitor of selective γ⁃chain cytokines, decreases leukemic T⁃cell viability［J］. Leukemia, 2019,33（5）:1243⁃1255. doi: 10.1038/s41375⁃018⁃0290⁃y.
［29］	Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition［J］. Nat Med, 2014,20（9）:1043⁃1049. doi: 10.1038/nm.3645.
［30］	Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. N Engl J Med, 2014,371（2）:130⁃139. doi: 10.1056/NEJMoa1314768.
［31］	Renert⁃Yuval Y, Guttman⁃Yassky E. A novel therapeutic paradigm for patients with extensive alopecia areata［J］. Expert Opin Biol Ther, 2016,16（8）:1005⁃1014. doi: 10.1080/14712598. 2016.1188076.
［32］	Penzi LR, Yasuda M, Manatis⁃Lornell A, et al. Hair regrowth in a patient with long⁃standing alopecia totalis and atopic dermatitis treated with dupilumab［J］. JAMA Dermatol, 2018,154（11）:1358⁃1360. doi: 10.1001/jamadermatol.2018.2976.
［34］	Marks DH, Mesinkovska N, Senna MM. Cause or cure? Review of dupilumab and alopecia areata［J］. J Am Acad Dermatol, 2019. doi: 10.1016/j.jaad.2019.06.010.
［35］	Renert⁃Yuval Y, Guttman⁃Yassky E. The changing landscape of alopecia areata: the therapeutic paradigm［J］. Adv Ther, 2017,34（7）:1594⁃1609. doi: 10.1007/s12325⁃017⁃0542⁃7.
［36］	Kasumagic⁃Halilovic E, Prohic A, Cavaljuga S. Tumor necrosis factor⁃alpha in patients with alopecia areata［J］. Indian J Dermatol, 2011,56（5）:494⁃496. doi: 10.4103/0019⁃5154.87124.
［37］	Özkur E, Altunay İK, Leblebici C, et al. Adalimumab⁃induced scalp psoriasis with severe alopecia［J］. Dermatol Ther, 2019,32（5）:e13033. doi: 10.1111/dth.13033.
［38］	Béné J, Moulis G, Auffret M, et al. Alopecia induced by tumour necrosis factor⁃alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmaco⁃vigilancedatabase［J］. Rheumatology （Oxford）, 2014,53（8）:1465⁃1469. doi: 10.1093/rheumatology/keu145.
［39］	Tauber M, Buche S, Reygagne P, et al. Alopecia areata occurring during anti⁃TNF therapy: a national multicenter prospective study［J］. J Am Acad Dermatol, 2014,70（6）:1146⁃1149. doi: 10.1016/j.jaad.2014.03.005.
［40］	Gorcey L, Gordon Spratt EA, Leger MC. Alopecia universalis successfully treated with adalimumab［J］. JAMA Dermatol, 2014,150（12）:1341⁃1344. doi: 10.1001/jamadermatol.2014.1544.
［41］	Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis［J］. Drugs, 2017,77（11）:1221⁃1233. doi: 10.1007/s40265⁃017⁃0775⁃4.

[1]	丁雨欣吕中法. 干细胞治疗斑秃的研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 835-838.
[2]	赵鹏秦小卫秦俊霞梁丽丽张馨中高杰. 白细胞介素18对斑秃患者自然杀伤细胞活性的调控[J]. 中华皮肤科杂志, 2022, 55(9): 778-783.
[3]	张宁李舒李敬. 免疫检查点抑制剂和靶向药物辅助治疗可切除黑素瘤疗效的网状Meta分析[J]. 中华皮肤科杂志, 2022, 55(7): 603-609.
[4]	赵鹏秦小卫秦俊霞梁丽丽张馨中高杰. 斑秃患者外周血白细胞介素35的表达及其对调节性T细胞的功能调控[J]. 中华皮肤科杂志, 2022, 55(3): 224-230.
[5]	章星琪. [开放获取] 斑秃与Th2型免疫反应[J]. 中华皮肤科杂志, 2022, 55(11): 1013-1018.
[6]	王冠钰王艺萌李薇薇张春雷. 复发/难治性皮肤T细胞淋巴瘤的非化疗药物新选择[J]. 中华皮肤科杂志, 2022, 0(1): 20210850-e20210850.
[7]	吉祥王大光. 皮肤鳞状细胞癌生物治疗的进展[J]. 中华皮肤科杂志, 2022, 0(1): 20220172-e20220172.
[8]	严汝帆廖洁月郭子瑜姚南周文玉罗帅寒天张桂英赵明. 天疱疮发病机制和靶向治疗的研究进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210248-e20210248.
[9]	隋长霖常晓赵琪朱威. 抗肿瘤靶向和免疫治疗致银屑病研究进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210442-e20210442.
[10]	蒋佳怡王大光. 非传染性炎症性甲病的诊疗进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210612-e20210612.
[11]	白璐楚妍刘园园朱才勇. 慢性手部湿疹的治疗进展[J]. 中华皮肤科杂志, 2022, 0(1): 20220028-e20220028.
[12]	曹蒙洪安澜王焱方方. 儿童黑素瘤临床研究进展[J]. 中华皮肤科杂志, 2022, 0(1): 20210158-e20210158.
[13]	王钰倩乔建军方红. 国内外斑秃诊疗指南/共识比较 [J]. 中华皮肤科杂志, 2022, 0(1): 20210184-e20210184.
[14]	高天文郭伟楠. 中国黑素瘤研究进展与新治疗策略[J]. 中华皮肤科杂志, 2021, 54(1): 27-32.
[15]	高艳, 王鹏, 康晓静. 卡波西肉瘤治疗研究新进展[J]. 中华皮肤科杂志, 2021, 0(1): 20210303-e20210303.

小分子靶向药物和生物制剂治疗斑秃的研究进展

Small-molecule targeted drugs and biological agents for alopecia areata

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

Metrics

本文评价

推荐阅读 10